Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Ramipril 10 mg Tablets
NCT05438316Phase 1Completed
- Sponsor
- Pharmtechnology
- Start
- Jun 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ramipril in hypertension (HTN) and heart failure (HF) (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve from time 0 to 72 hours. Started Jun 2022; status: completed.
02
Drugs
ramipril
03
Conditions
hypertension (HTN)heart failure (HF)
Beyond the preview
Go deeper on NCT05438316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438316.